Open AccessIn vitro activity of U-63196E, a new cephalosporin, against clinical bacterial isolates
Author(s) -
George M. Eliopoulos,
A Gardella,
Paola C. DeGirolami,
R C Moellering
Publication year - 1984
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.25.4.401
Subject(s) - cefoperazone , cephalosporin , cefotaxime , moxalactam , microbiology and biotechnology , piperacillin , pseudomonas aeruginosa , cefsulodin , tobramycin , in vitro , antibiotics , biology , chemistry , bacteria , imipenem , gentamicin , antibiotic resistance , biochemistry , genetics
The in vitro activity of U-63196E, a new cephalosporin, was compared with those of other extended-spectrum cephalosporins and penicillins against clinical bacterial isolates. Against Pseudomonas aeruginosa, the activity of U-63196E was comparable to those of cefoperazone and piperacillin, each of which inhibited 90% of strains at concentrations of less than or equal to 16 micrograms/ml. The new drug also demonstrated activity against a variety of other bacterial species, but it was generally less active than cefotaxime, moxalactam, and cefoperazone against members of the family Enterobacteriaceae and staphylococci. The presence of any 1 of 10 plasmid-mediated beta-lactamases in a series of otherwise isogenic laboratory strains of P. aeruginosa resulted in a significant reduction in the activity of U-63196E in comparison with its activity against the parent strain, which lacks these enzymes. Combinations of U-63196E with tobramycin demonstrated bacteriostatic synergism against 11 of 20 clinical isolates of P. aeruginosa.